MUC15 Antibody

What is MUC15 and why is it relevant for cancer research?

MUC15 (also known as PAS3 or MUC-15) is a cell surface-associated mucin protein with a molecular weight of approximately 36.3 kilodaltons . Recent research has established MUC15 as a tumor suppressor gene in esophageal squamous cell carcinoma (ESCC), where its expression is significantly downregulated in tumor tissues compared to normal tissues . The protein has been demonstrated to inhibit proliferation and migration potential of ESCC cells both in vitro and in vivo, suggesting its important role in cancer progression . MUC15 expression correlates with the degree of tumor differentiation and serves as an independent prognostic factor for patient survival, making it a promising biomarker and potential therapeutic target for ESCC and possibly other cancer types .

What are the primary applications for MUC15 antibodies in research?

MUC15 antibodies are primarily utilized in several key research applications:

• Western Blot (WB): For detection and quantification of MUC15 protein expression levels in cell or tissue lysates

• Immunohistochemistry (IHC): For visualization of MUC15 expression patterns in tissue sections, particularly in comparing tumor versus normal tissues

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of MUC15 in solution

• Immunoprecipitation: For isolating MUC15 and its binding partners to study protein-protein interactions

• Flow Cytometry: For analyzing MUC15 expression on cell surfaces in various cell populations

These applications enable researchers to investigate MUC15's expression patterns, correlate them with disease states, and explore its functional roles in various biological processes and pathological conditions .

How should MUC15 antibody specificity be validated before experimental use?

Validating MUC15 antibody specificity is crucial for generating reliable research data. A comprehensive validation approach should include:

• Western blot analysis: Confirm a single band at the expected molecular weight (~36.3 kDa) in tissues/cells known to express MUC15

• Positive and negative controls: Use tissues/cell lines with known MUC15 expression levels (e.g., normal esophageal tissue as positive control, certain ESCC cell lines as negative controls)

• Recombinant protein controls: Test antibody reactivity against purified recombinant MUC15 protein

• siRNA/shRNA knockdown validation: Demonstrate reduced antibody staining in cells where MUC15 has been knocked down

• Cross-reactivity testing: Verify antibody specificity against other mucin family members, particularly those with similar structural domains

• Peptide competition assays: Pre-incubation with the immunizing peptide should abolish specific binding

Combining multiple validation methods provides the strongest evidence for antibody specificity and reliability for downstream applications .

How should researchers design experiments to investigate MUC15's role as a tumor suppressor?

To rigorously investigate MUC15's tumor suppressor function, researchers should implement a multi-faceted experimental approach:

• Expression analysis in clinical samples:

  • Compare MUC15 expression in paired tumor and adjacent normal tissues using IHC and Western blot

  • Correlate expression levels with clinical parameters (tumor grade, stage, patient survival)

• In vitro functional assays:

  • Overexpression studies: Generate stable cell lines overexpressing MUC15 to assess effects on:

    • Proliferation (CCK8, EdU incorporation assays)

    • Migration (wound healing assays)

    • Invasion (Matrigel invasion assays)

    • Cell cycle progression and apoptosis (flow cytometry)

  • Knockdown/knockout studies: Use siRNA or CRISPR/Cas9 to reduce MUC15 expression and assess the same parameters

• In vivo tumor models:

  • Xenograft models using MUC15-overexpressing versus control cells to assess tumor growth rate, volume, and metastatic potential

  • Patient-derived xenografts to evaluate MUC15 expression in a more clinically relevant context

• Mechanism investigation:

  • Identify downstream signaling pathways using phosphoprotein arrays

  • RNA-seq to identify transcriptional changes

  • Co-immunoprecipitation to identify protein interaction partners

  • Chromatin immunoprecipitation to assess transcriptional regulation

This comprehensive approach allows for robust validation of MUC15's tumor suppressor functions across multiple experimental systems and helps elucidate the underlying mechanisms .

How can researchers effectively use MUC15 antibodies to study its regulation during viral infection?

For studying MUC15 regulation during viral infection, researchers should implement the following methodological approaches:

• Temporal expression profiling:

  • Monitor MUC15 expression changes at multiple time points post-infection using qRT-PCR and Western blot

  • Compare active infection with UV-inactivated virus to distinguish between replication-dependent and independent mechanisms

• Subcellular localization analysis:

  • Use immunofluorescence microscopy with MUC15 antibodies to track changes in protein localization during infection

  • Perform subcellular fractionation followed by Western blot to quantify shifts between membrane, cytoplasmic, and nuclear compartments

• Promoter analysis:

  • Identify regulatory elements in the MUC15 promoter region using reporter assays

  • Perform ChIP assays to identify transcription factors binding to the MUC15 promoter during infection

• Signaling pathway dissection:

  • Use specific inhibitors of pathways activated during viral infection (e.g., ERK pathway)

  • Monitor changes in MUC15 expression to identify regulatory mechanisms

• Functional assays:

  • Pre-treat cells with recombinant MUC15 protein before infection to assess protective effects

  • Perform post-infection treatment to evaluate therapeutic potential

  • Measure viral titers (plaque assays) and viral protein expression (Western blot) to quantify effects on viral replication

This systematic approach will provide insights into both the mechanisms regulating MUC15 expression during infection and its potential antiviral functions .

What optimization strategies should be employed for MUC15 detection in immunohistochemistry?

For optimal MUC15 detection in immunohistochemistry, researchers should consider the following methodological optimization strategies:

• Tissue preservation and fixation:

  • Compare formalin-fixed paraffin-embedded (FFPE) versus frozen sections

  • Optimize fixation time to preserve MUC15 epitopes (typically 12-24 hours in 10% neutral buffered formalin)

  • Consider alternative fixatives if standard protocols yield poor results

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods:

    • Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)

    • HIER with EDTA buffer (pH 9.0)

    • Enzymatic retrieval with proteinase K

  • Optimize retrieval times (15-30 minutes) and temperatures

• Antibody selection and titration:

  • Compare multiple anti-MUC15 antibodies targeting different epitopes

  • Perform antibody dilution series (typically 1:100 to 1:1000) to determine optimal concentration

  • Consider the use of conjugated versus unconjugated primary antibodies

• Detection system selection:

  • Compare sensitivity of different detection systems:

    • HRP-polymer based systems

    • Avidin-biotin complex (ABC) method

    • Tyramide signal amplification for low abundance targets

• Controls implementation:

  • Include positive tissue controls (normal esophageal tissue)

  • Negative controls (omitting primary antibody)

  • Blocking peptide controls to confirm specificity

• Counterstaining and signal quantification:

  • Optimize hematoxylin counterstaining time for clear nuclear visualization

  • Implement digital image analysis for quantitative assessment of MUC15 expression

By systematically optimizing these parameters, researchers can achieve consistent, specific, and sensitive detection of MUC15 in tissue samples for accurate assessment of expression patterns in normal and pathological states .

What methods are recommended for studying MUC15 interactions with other proteins?

For investigating MUC15 protein interactions, researchers should employ multiple complementary approaches:

• Co-immunoprecipitation (Co-IP):

  • Use anti-MUC15 antibodies to pull down protein complexes from cell lysates

  • Perform reverse Co-IP with antibodies against suspected interaction partners

  • Optimize lysis conditions to preserve membrane protein interactions:

    • Use mild detergents (0.5-1% NP-40, 0.5% Triton X-100)

    • Include protease and phosphatase inhibitors

    • Consider crosslinking for transient interactions

• Proximity ligation assay (PLA):

  • Visualize protein interactions in situ with subcellular resolution

  • Requires antibodies against both MUC15 and interaction partners from different species

  • Particularly useful for membrane protein interactions in their native context

• Bimolecular fluorescence complementation (BiFC):

  • Generate fusion proteins of MUC15 and potential partners with split fluorescent protein fragments

  • Interaction brings fragments together, restoring fluorescence

  • Allows visualization of interactions in living cells

• Mass spectrometry-based approaches:

  • Immunoprecipitate MUC15 followed by LC-MS/MS analysis

  • SILAC or TMT labeling for quantitative comparison between conditions

  • Crosslinking mass spectrometry (XL-MS) to map interaction interfaces

• Protein-protein interaction screening:

  • Yeast two-hybrid or mammalian two-hybrid for systematic screening

  • Protein microarrays to identify binding partners from purified proteins

By combining these complementary techniques, researchers can build a comprehensive interactome map for MUC15 and validate key interactions with functional significance .

How can researchers effectively study the role of MUC15 in immune cell interactions?

To investigate MUC15's role in immune cell interactions, researchers should implement the following methodological approaches:

• Correlation analysis in clinical samples:

  • Perform dual immunofluorescence staining for MUC15 and immune cell markers

  • Use computational methods like CIBERSORT to analyze immune cell infiltration patterns

  • Correlate MUC15 expression with specific immune cell populations (plasma cells, monocytes, T cell subsets)

• Co-culture systems:

  • Establish co-culture models of MUC15-expressing cells with immune cells

  • Compare wild-type versus MUC15-overexpressing or MUC15-knockout cells

  • Measure immune cell activation markers, cytokine production, and functional responses

  • Analyze changes in MUC15-expressing cells following immune cell interaction

• Recombinant protein studies:

  • Treat immune cells with purified recombinant MUC15 protein

  • Assess changes in immune cell phenotype, activation status, and function

  • Perform dose-response and time-course experiments

• Signaling pathway analysis:

  • Monitor activation of immune signaling pathways (NF-κB, STAT, MAPK)

  • Use specific pathway inhibitors to dissect mechanisms

  • Assess phosphorylation of key signaling molecules by Western blot

• In vivo models:

  • Generate MUC15 conditional knockout mice in specific immune cell populations

  • Analyze immune cell development, activation, and function

  • Study effects on tumor immunity in cancer models

This multi-faceted approach will provide mechanistic insights into how MUC15 influences immune cell functions and how these interactions might be exploited therapeutically .

How should researchers analyze MUC15 expression data from cancer studies?

For rigorous analysis of MUC15 expression data in cancer studies, researchers should implement the following methodological framework:

This comprehensive analytical approach enables researchers to establish MUC15's clinical relevance, prognostic value, and potential as a therapeutic target in cancer .

What statistical approaches are recommended for analyzing differences in MUC15 expression between experimental conditions?

When analyzing MUC15 expression differences between experimental conditions, researchers should employ the following statistical framework:

• Data preprocessing and normalization:

  • For Western blot: Normalize MUC15 band intensity to loading controls (GAPDH, β-actin)

  • For qRT-PCR: Use validated reference genes for ΔΔCt calculations

  • For IHC: Standardize staining quantification methods (H-score, percentage positive cells)

• Determining appropriate statistical tests:

  • For two-group comparisons:

    • Parametric: Student's t-test (if normally distributed)

    • Non-parametric: Mann-Whitney U test (if not normally distributed)

  • For multiple group comparisons:

    • Parametric: One-way ANOVA with post-hoc tests (Tukey, Bonferroni)

    • Non-parametric: Kruskal-Wallis with Dunn's post-hoc test

  • For time-course experiments:

    • Repeated measures ANOVA or mixed-effects models

• Sample size and power calculations:

  • Calculate appropriate sample sizes based on:

    • Expected effect size (from preliminary data)

    • Desired statistical power (typically 0.8)

    • Significance level (α=0.05)

  • Report power calculations in methods section

• Multiple testing correction:

  • Apply appropriate corrections for multiple comparisons:

    • Bonferroni correction (conservative)

    • False Discovery Rate (FDR) methods (Benjamini-Hochberg)

  • Report both raw and adjusted p-values

• Data visualization:

  • Use appropriate plots to represent data:

    • Box plots showing median, quartiles, and outliers

    • Violin plots for distributional information

    • Bar graphs with individual data points for transparency

  • Include error bars representing standard deviation or standard error

This systematic statistical approach ensures robust, reproducible analysis of MUC15 expression data across experimental conditions.

What are the common challenges in MUC15 Western blotting and how can they be addressed?

Researchers frequently encounter several challenges when performing Western blotting for MUC15. Here are methodological solutions for common issues:

• Poor signal or no detection:

  • Optimization strategy: Increase primary antibody concentration (try 1:250 instead of 1:500)

  • Sample preparation: Use stronger lysis buffers (RIPA with 0.1% SDS) for membrane proteins

  • Protein loading: Increase total protein amount (50-80 μg instead of standard 20-30 μg)

  • Transfer efficiency: Optimize transfer time for high molecular weight proteins (increase to 2 hours or overnight at 4°C)

  • Blocking optimization: Try different blocking agents (5% BSA instead of milk for phospho-epitopes)

• Multiple bands or non-specific binding:

  • Antibody selection: Test multiple antibodies targeting different epitopes

  • Blocking optimization: Increase blocking time (2 hours) and concentration (5% to 7%)

  • Washing stringency: Add 0.2% Tween-20 instead of standard 0.1% to reduce background

  • Antibody validation: Perform peptide competition assay to identify specific bands

  • Secondary antibody: Use secondary antibodies specific to light chains to avoid heavy chain detection

• Inconsistent results between experiments:

  • Standardization: Develop a detailed SOP for sample collection and processing

  • Internal controls: Always include positive control samples with known MUC15 expression

  • Loading controls: Use multiple loading controls (GAPDH and total protein staining)

  • Quantification: Implement digital image analysis with standardized exposure settings

• Degradation issues:

  • Sample handling: Process samples on ice and include protease inhibitor cocktails

  • Storage conditions: Store samples at -80°C and avoid repeated freeze-thaw cycles

  • Denaturing conditions: Optimize SDS concentration and heating time/temperature

By implementing these methodological refinements, researchers can achieve consistent and specific detection of MUC15 in Western blotting experiments .

How can researchers optimize MUC15 recombinant protein experiments?

When working with MUC15 recombinant protein for functional studies, researchers should implement the following optimization strategies:

• Protein quality assessment:

  • Verify purity by SDS-PAGE (>90% recommended)

  • Confirm identity by mass spectrometry

  • Test biological activity in dose-response experiments

  • Check for endotoxin contamination (<1 EU/μg protein)

• Concentration optimization:

  • Perform detailed dose-response experiments:

    • Low doses: 1-5 ng/ml

    • Medium doses: 10-50 ng/ml

    • High doses: 100-500 ng/ml

  • Determine both effective concentration (EC50) and potential inhibitory concentrations

• Treatment timing optimization:

  • Compare pre-treatment vs. post-treatment protocols:

    • Pre-treatment: Incubate target cells with rMUC15 before stimulation/infection

    • Co-treatment: Add rMUC15 simultaneously with stimulus/infection

    • Post-treatment: Add rMUC15 after stimulation/infection

  • Perform time-course experiments (15 min, 30 min, 1h, 2h, 4h, 24h, 48h)

• Buffer and carrier optimization:

  • Test different carrier proteins (0.1% BSA, 0.1% human serum albumin)

  • Optimize buffer composition (PBS vs. serum-free media)

  • Consider adding protease inhibitors for long-term experiments

• Storage and handling:

  • Aliquot protein to avoid freeze-thaw cycles

  • Determine optimal storage conditions (-80°C vs. -20°C)

  • Test protein stability at experimental temperatures (4°C, room temperature, 37°C)

• Functional readouts:

  • Implement multiple complementary assays:

    • Binding assays (ELISA, surface plasmon resonance)

    • Cell-based functional assays (proliferation, migration)

    • Signaling pathway activation (phospho-specific Western blots)

By systematically optimizing these parameters, researchers can ensure reproducible and physiologically relevant results when using MUC15 recombinant protein in their experiments .

How is MUC15 research evolving in the context of cancer immunotherapy?

MUC15 research is increasingly intersecting with cancer immunotherapy, opening several promising research avenues:

• Immune checkpoint modulation:

  • Investigate potential correlations between MUC15 expression and response to immune checkpoint inhibitors

  • Study interactions between MUC15 and immune checkpoint molecules (PD-1, PD-L1, CTLA-4)

  • Explore combination approaches targeting both MUC15 and immune checkpoints

• T cell response modulation:

  • Characterize how MUC15 influences T cell recruitment, activation, and function

  • Investigate the correlation between MUC15 and T cell follicular helper populations in the tumor microenvironment

  • Develop strategies to enhance T cell responses by modulating MUC15 expression or function

• Innate immune cell interactions:

  • Study MUC15's effects on monocytes and macrophage polarization (M1 vs. M2)

  • Investigate interactions with dendritic cells and natural killer cells

  • Examine how MUC15 modulates innate immune responses in the tumor microenvironment

• MUC15-targeted immunotherapies:

  • Develop MUC15-specific chimeric antigen receptor (CAR) T cells

  • Explore MUC15-targeted antibody-drug conjugates

  • Investigate MUC15 peptide vaccines to induce anti-tumor immunity

• Biomarker development:

  • Evaluate MUC15 as a predictive biomarker for immunotherapy response

  • Develop multiplexed assays combining MUC15 with immune cell markers

  • Correlate MUC15 expression patterns with immune infiltration and clinical outcomes

This emerging research direction represents a promising intersection between MUC15 biology and cancer immunotherapy, with potential to develop novel therapeutic strategies and predictive biomarkers .

What are the methodological approaches for investigating MUC15's role in signaling pathways?

To comprehensively investigate MUC15's role in cellular signaling pathways, researchers should implement the following methodological framework:

• Phosphoprotein analysis:

  • Perform phosphoprotein arrays after MUC15 overexpression or knockdown

  • Use phospho-specific antibodies to monitor key signaling molecules (ERK, AKT, STAT)

  • Implement time-course experiments to capture signaling dynamics

  • Compare baseline vs. stimulated conditions (growth factors, inflammatory cytokines)

• Proximity-based interaction mapping:

  • Use BioID or APEX2 proximity labeling fused to MUC15

  • Identify proteins in close proximity to MUC15 in living cells

  • Compare interactome changes under different conditions (normal vs. stress)

• Domain-specific mutation analysis:

  • Generate MUC15 constructs with mutations in key domains:

    • Cytoplasmic domain mutations to disrupt signaling

    • Transmembrane domain mutations to affect localization

    • Extracellular domain mutations to alter ligand binding

  • Assess effects on downstream signaling pathway activation

• Inhibitor-based pathway dissection:

  • Use small molecule inhibitors targeting specific pathways:

    • MEK/ERK inhibitors (U0126, PD98059)

    • PI3K/AKT inhibitors (LY294002, Wortmannin)

    • JAK/STAT inhibitors (Ruxolitinib, Tofacitinib)

  • Determine which pathways are essential for MUC15-mediated effects

• Transcriptional regulation analysis:

  • Perform RNA-seq after MUC15 modulation

  • Use pathway enrichment analysis to identify regulated pathways

  • Validate key targets by qRT-PCR and protein expression

  • Implement ChIP-seq to identify transcription factors involved

By systematically applying these complementary approaches, researchers can build a comprehensive map of MUC15's role in cellular signaling networks and identify potential therapeutic targets for intervention .

What experimental protocols are recommended for validating new anti-MUC15 antibodies?

For comprehensive validation of new anti-MUC15 antibodies, researchers should implement the following standardized protocol sequence:

• Initial specificity screening:

  • Western blot analysis:

    • Test antibody on lysates from multiple cell lines with varying MUC15 expression

    • Include recombinant MUC15 protein as positive control

    • Verify single band at expected molecular weight (~36.3 kDa)

    • Compare results with commercially validated antibodies

• Genetic validation:

  • Overexpression controls:

    • Test antibody on cells transfected with MUC15 expression vector

    • Include empty vector controls

    • Verify increased signal intensity proportional to expression level

  • Knockdown/knockout controls:

    • Test antibody on cells with siRNA-mediated MUC15 knockdown

    • Test antibody on CRISPR/Cas9 MUC15 knockout cells

    • Verify decreased/absent signal

• Epitope mapping and cross-reactivity:

  • Peptide competition assays:

    • Pre-incubate antibody with immunizing peptide

    • Verify signal abolishment in Western blot and IHC

  • Cross-reactivity testing:

    • Test reactivity against other mucin family members

    • Test specificity across species (if claiming cross-reactivity)

• Application-specific validation:

  • Immunohistochemistry:

    • Optimize fixation and antigen retrieval conditions

    • Test on tissue microarrays with known MUC15 expression patterns

    • Compare with RNA expression data from the same tissues

  • Immunofluorescence:

    • Verify appropriate subcellular localization (cell membrane)

    • Co-stain with membrane markers for colocalization

  • Flow cytometry:

    • Compare with isotype controls

    • Validate on cells with varying MUC15 expression levels

• Reproducibility assessment:

  • Test antibody performance across:

    • Different lots

    • Different sample preparation methods

    • Different detection systems

    • Multiple operators

This comprehensive validation protocol ensures antibody specificity, sensitivity, and reliability across different experimental applications .

What are the current gaps in MUC15 research and recommended methodological approaches to address them?

Current MUC15 research has several knowledge gaps that require specific methodological approaches:

• Structure-function relationships:

  • Gap: Limited understanding of MUC15's structural domains and their functions

  • Recommended approach:

    • Cryo-EM or X-ray crystallography of MUC15 protein

    • Domain deletion/mutation studies to correlate structure with function

    • Molecular dynamics simulations to predict structural interactions

• Downstream signaling mechanisms:

  • Gap: Incomplete characterization of MUC15's signaling pathways

  • Recommended approach:

    • Phosphoproteomics following MUC15 modulation

    • CRISPR screens to identify essential mediators of MUC15 function

    • Temporal signaling analyses with pathway-specific reporters

• Transcriptional regulation:

  • Gap: Limited knowledge of factors controlling MUC15 expression

  • Recommended approach:

    • Promoter analysis and reporter assays

    • ChIP-seq to identify transcription factor binding

    • CRISPR activation/inhibition screens targeting the MUC15 locus

• Immune system interactions:

  • Gap: Emerging but incomplete understanding of MUC15's immune functions

  • Recommended approach:

    • Single-cell RNA-seq of immune populations in MUC15-high vs. low environments

    • Spatial transcriptomics to map MUC15-immune cell interactions in tissues

    • In vivo models with tissue-specific MUC15 modulation

• Therapeutic targeting:

  • Gap: Underdeveloped strategies for modulating MUC15 therapeutically

  • Recommended approach:

    • Development of specific MUC15-targeting antibodies

    • Small molecule screens for MUC15 function modulators

    • Testing combination approaches with established therapies

• Clinical translation:

  • Gap: Limited validation in diverse patient cohorts

  • Recommended approach:

    • Multi-center retrospective studies with standardized MUC15 detection

    • Prospective biomarker studies in clinical trials

    • Development of companion diagnostics for MUC15-based therapies

These methodological approaches would address critical knowledge gaps and advance MUC15 research toward clinical applications .

How might MUC15 research evolve over the next decade?

MUC15 research is poised for significant advancement in the next decade, with several key developments anticipated:

• Expanded role in cancer biology:

  • Beyond the established tumor suppressor function in ESCC , MUC15's role will likely be characterized in additional cancer types

  • Integration of MUC15 expression data with multi-omics datasets will reveal context-dependent functions

  • Development of predictive models incorporating MUC15 status for patient stratification

• Therapeutic applications:

  • Development of MUC15-targeted therapies for cancers with altered expression

  • Combination approaches leveraging MUC15's effects on the tumor microenvironment

  • Gene therapy approaches to restore MUC15 expression in tumors with downregulation

• Diagnostic and prognostic implementations:

  • Standardized clinical assays for MUC15 detection in tissue samples

  • Liquid biopsy approaches for non-invasive monitoring of MUC15 status

  • Integration of MUC15 into multi-biomarker panels for improved prognostication

• Immune system modulation:

  • Detailed characterization of MUC15's interactions with diverse immune cell populations

  • Engineering of immune cells to respond to or target MUC15

  • Development of strategies to reprogram the immune microenvironment through MUC15 modulation

• Infectious disease applications:

  • Expansion of understanding MUC15's role in viral infections beyond the current findings

  • Potential development of MUC15-based antiviral strategies

  • Investigation of MUC15's role in bacterial and fungal infections

• Technological innovations:

  • Development of more specific and versatile anti-MUC15 antibodies

  • Advanced imaging techniques for visualizing MUC15 dynamics in living systems

  • AI-assisted analysis of MUC15 expression patterns and correlations